Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
In this analysis of a large patient pool from 2 open-label trials, long-term adjunctive LCM was efficacious and generally well tolerated in children with epilepsy and focal-onset or generalized seizures. Behavior and executive functioning were generally stable without observable worsening during long-term adjunctive LCM treatment.
Authors
- Carrie McClung
- J. Eric Piña-Garza
- Cynthia Beller (ORCID: https://orcid.org/0009-0006-4388-1241)
- Mark Kristof Farkas (ORCID: https://orcid.org/0000-0002-6016-2883)
- Brian D. Moseley (ORCID: https://orcid.org/0000-0001-8573-7340)
- Iryna Makedonska
- Dimitrios Bourikas (ORCID: https://orcid.org/0009-0005-4503-0734)
- Florin Floricel (ORCID: https://orcid.org/0009-0008-4982-1092)
- Sheila Therriault
- Christine de la Loge (ORCID: https://orcid.org/0000-0002-5896-5927)
- Svetlana Dimova (ORCID: https://orcid.org/0000-0001-7014-0007)
Institutions
- Semmelweis University (HU)
- Children's Oncology Group (CH)
- Dimitrie Cantemir Christian University (RO)
- UCB Pharma (United States) (US)
- Regional Clinical Hospital named after II Mechnikov (UA)
- UCB Pharma (Germany) (DE)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Epilepsy & Behavior
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.yebeh.2024.109989
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- UCB Pharma
- UCB Celltech